ASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914
EAU Podcasts - Un podcast de European Association of Urology - Les dimanches
Catégories:
In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Assoc. Prof. Pedro Barata from University Hospitals Seidman Cancer Center, USA, about the results of two adjuvant RCC studies: KEYNOTE-564; and CheckMate-914.Assoc. Prof. Barata explains the positive trial results of KEYNOTE-564, which is the first time there has been an overall survival advantage with a PD-1 inhibitor in the pure adjuvant setting in RCC. These results support adjuvant pembrolizumab as a standard of care...
